Zollikerberg, Switzerland

Oskar Jeger

This inventor holds 1 USPTO granted patent. Top assignee: Ciba-Geigy Corporation. Active years: 1976.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 1976

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Oskar Jeger: Innovator in Steroid Chemistry

Introduction

Oskar Jeger is a notable inventor based in Zollikerberg, Switzerland. He has made significant contributions to the field of steroid chemistry, particularly in the selective reduction of steroid compounds. His work has implications for the synthesis of pharmacologically interesting substances.

Latest Patents

Oskar Jeger holds a patent for a process related to the manufacture of 1 patent. The invention focuses on the selective reduction of the 20-oxo group in Δ16-steroid-14β,18-diol-20-ones of the pregnane series. This process is designed to produce two epimeric 20-alcohols with 20S and 20R configurations. It is particularly aimed at the manufacture of alkaloids of the batrachotoxin type, including batrachotoxinine A, which features a 20S alcohol grouping. The method involves reducing the Δ16-steroid-14β,18-diol-20-ones in the form of their 14,18-ketals, utilizing complex light metal hydrides and operating at specific temperatures. The separation of the resulting isomers can be achieved through standard physical operations such as crystallization or chromatography.

Career Highlights

Oskar Jeger has had a distinguished career, working at Ciba-Geigy Corporation, a prominent player in the pharmaceutical and chemical industries. His innovative approaches to steroid chemistry have positioned him as a key figure in the development of new pharmaceutical compounds.

Collaborations

Oskar has collaborated with Hansuli Wehrli, contributing to advancements in their field through shared expertise and innovative research.

Conclusion

Oskar Jeger's work exemplifies the intersection of innovation and practical application in steroid chemistry. His contributions continue to influence the development of important pharmacological substances.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…